Ensoma – a genomic medicines company developing one-time in vivo treatments that precisely engineer any cell of the hematopoietic system – announced the closing of an extension of its Series B financing by $50 million, bringing the total size of the funding round to $135 million. The $50 million funding round was contributed by new investors Kite, a Gilead Company, Bioluminescence Ventures, and Delos Capital and by existing investor SymBiosis.
These investors joined a syndicate of leading healthcare funds to advance the development of Ensoma’s Engenious in vivo engineered cell therapy platform and pipeline of genomic medicines for immuno-oncology, genetic disease and other therapeutic applications.
Other investors in the Series B included 5AM Ventures, Arix Bioscience, Alexandria Venture Investments, the Bill & Melinda Gates Foundation, Catalio Capital Management, Cormorant Asset Management, F-Prime Capital, Fred Hutchinson Cancer Center, Mirae Asset, Qatar Investment Authority (QIA), Solasta Ventures, Takeda Ventures, and Viking Global Investors.
KEY QUOTES:
“Ensoma is creating a new generation of smart immune cell medicines by harnessing the concerted power of multiple immune cell types. There are millions of patients that need better answers. With this financing, we are well positioned to bring our breakthrough therapies to the clinic.”
— Emile Nuwaysir, Ph.D., chief executive officer of Ensoma
“Ensoma’s Engenious platform brings together delivery and engineering capabilities to unlock the full promise of in vivo multiplexed therapies. We are very excited about working with the Ensoma team to make this a reality.”
— Bioluminescence Ventures managing partner Dr. Kouki Harasaki – who is joining the Ensoma’s Board of Directors in connection with the extension funding
